FSA Advisors Inc. Purchases 9,972 Shares of AbbVie Inc. $ABBV

Key Points

• FSA Advisors Inc. raised its stake in AbbVie by 473.5% in Q4, buying 9,972 shares to hold 12,078 shares valued at about $2.76 million.
• Q1 earnings beat and outlook upgrade: AbbVie topped Q1 estimates, raised its 2026 guidance with Skyrizi and Rinvoq offsetting Humira declines, spurring multiple analyst upgrades and a MarketBeat consensus "Moderate Buy" target of $252.90.
• Insider selling and pipeline moves — executives sold sizable blocks (EVP sold 22,381 shares), the company cut a cancer candidate, and while institutions own ~70.2% of the stock, insiders hold only 0.06%, creating near‑term sentiment risks.

FSA Advisors Inc. raised its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 473.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,078 shares of the company's stock after buying an additional 9,972 shares during the quarter. FSA Advisors Inc.'s holdings in AbbVie were worth $2,760,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Reynders McVeigh Capital Management LLC increased its holdings in AbbVie by 2.4% in the 4th quarter. Reynders McVeigh Capital Management LLC now owns 28,750 shares of the company's stock valued at $6,569,000 after buying an additional 680 shares during the period. Mcdonald Partners LLC increased its holdings in AbbVie by 1.9% in the 4th quarter. Mcdonald Partners LLC now owns 19,967 shares of the company's stock valued at $4,562,000 after buying an additional 378 shares during the period. Core Alternative Capital increased its holdings in AbbVie by 661.5% in the 4th quarter. Core Alternative Capital now owns 2,155 shares of the company's stock valued at $492,000 after buying an additional 1,872 shares during the period. AlphaStar Capital Management LLC increased its holdings in AbbVie by 4.3% in the 4th quarter. AlphaStar Capital Management LLC now owns 25,257 shares of the company's stock valued at $5,771,000 after buying an additional 1,033 shares during the period. Finally, Woodard & Co. Asset Management Group Inc. ADV grew its holdings in shares of AbbVie by 2.0% during the 4th quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 8,340 shares of the company's stock valued at $1,906,000 after purchasing an additional 166 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Bank of America raised shares of AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price target on the stock in a report on Thursday. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price target on the stock. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus target price of $252.90.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by insiders.

AbbVie Trading Up 0.0%

Shares of AbbVie stock opened at $206.63 on Monday. The firm has a market capitalization of $365.36 billion, a PE ratio of 101.79, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The firm's 50 day moving average is $214.55 and its 200 day moving average is $221.49. AbbVie Inc. has a 1 year low of $176.57 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the firm posted $2.46 EPS. The company's revenue for the quarter was up 12.4% compared to the same quarter last year. As a group, research analysts anticipate that AbbVie Inc. will post 14.29 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie's payout ratio is 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.